NLRP3 and Alzheimer disease: Several therapeutic agents targeting the NLRP3 inflammasome, either directly or indirectly, have shown promise in preclinical AD models but have not yet advanced beyond early-phase clinical trials for AD, often due to challenges in brain penetration and trial design for neurodegenerative diseases.